Replies to post #384691 on Amarin Corp Plc (AMRN)

[HDGabor]

i-

Look at the bright side. At this rate, Generics will overtake the brand, so proving infringement should be a lock.

No question about that, but Hikma was taken off the infringement suit. Everything has been turned upside down when it cones to Amarin.

Are they just saying that the Generics are only making the drug available and nit inducing? Why didn’t that work for Teva vs GSK?

That's the billions of dollars question?

Market share of the generic (the sold quantity) is not a measurement for infringement by generics. They could have 100% market share but w/o inducement - only making the drug available is not an inducement - they are not liable for infringement (by other participant (s)).

Best,
G